Mineralys Therapeutics, Inc. has announced a public offering of $175.0 million of its common stock. The underwriters may purchase an additional $26.25 million of shares. Proceeds will fund clinical development of lorundrostat and other activities. BofA Securities, Evercore ISI, Goldman Sachs, Stifel, and Wells Fargo Securities are managing the offering. Mineralys intends to use the funds for research, manufacturing, and general corporate purposes. The offering is subject to market conditions. The securities are being offered under a shelf registration statement. Mineralys is a biopharmaceutical company focused on hypertension and related diseases.

Read more at GlobeNewswire: Mineralys Therapeutics Announces Proposed Public Offering